Artículos de revistas sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Minchom, Anna, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Andrew Wotherspoon, Susana Miranda et al. "Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab". Journal for ImmunoTherapy of Cancer 8, n.º 1 (marzo de 2020): e000713. http://dx.doi.org/10.1136/jitc-2020-000713.
Texto completoMahadevan, Daruka, Li Ma, Kai Treuner, Jenna Wong y Catherine Schnabel. "330 Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (noviembre de 2021): A356. http://dx.doi.org/10.1136/jitc-2021-sitc2021.330.
Texto completoSokol, Ethan, Natalie Danziger, Dean Pavlick, Julia Andrea Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas I. Lin et al. "Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 3558. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3558.
Texto completoLujambio, Amaia. "The more (mutations), the better". Science Translational Medicine 11, n.º 477 (30 de enero de 2019): eaaw5320. http://dx.doi.org/10.1126/scitranslmed.aaw5320.
Texto completoHsiehchen, David, Magdalena Espinoza, Cristina Valero, Chul Ahn y Luc G. T. Morris. "Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups". Journal for ImmunoTherapy of Cancer 9, n.º 11 (noviembre de 2021): e003683. http://dx.doi.org/10.1136/jitc-2021-003683.
Texto completoAn, Ho Jung, Hong Jae Chon y Chan Kim. "Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors". International Journal of Molecular Sciences 22, n.º 17 (30 de agosto de 2021): 9414. http://dx.doi.org/10.3390/ijms22179414.
Texto completoGiordano, Frank A., Marlon R. Veldwijk, Carsten Herskind y Frederik Wenz. "Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math". Strahlentherapie und Onkologie 194, n.º 10 (20 de julio de 2018): 873–75. http://dx.doi.org/10.1007/s00066-018-1341-z.
Texto completoDuchemann, Boris, Jordi Remon, Marie Naigeon, Laura Mezquita, Roberto Ferrara, Lydie Cassard, Jean Mehdi Jouniaux et al. "Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer". Cancers 12, n.º 12 (3 de diciembre de 2020): 3625. http://dx.doi.org/10.3390/cancers12123625.
Texto completoAcosta-Medina, Aldo A., Jithma P. Abeykoon, Surendra Dasari, Antonious Z. Hazim, N. Nora Bennani, Terra Lasho, Aishwarya Ravindran et al. "Tumor Mutational Burden in Histiocytic Neoplasms". Blood 138, Supplement 1 (5 de noviembre de 2021): 3634. http://dx.doi.org/10.1182/blood-2021-153128.
Texto completoBielska, Agata A., Walid K. Chatila, Henry Walch, Nikolaus Schultz, Zsofia K. Stadler, Jinru Shia, Diane Reidy-Lagunes y Rona Yaeger. "Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance". Journal of the National Comprehensive Cancer Network 19, n.º 2 (febrero de 2021): 130–33. http://dx.doi.org/10.6004/jnccn.2020.7680.
Texto completoSicard, Guillaume, Frédéric Fina, Raphaelle Fanciullino, Fabrice Barlesi y Joseph Ciccolini. "Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy". Pharmaceutics 12, n.º 8 (11 de agosto de 2020): 758. http://dx.doi.org/10.3390/pharmaceutics12080758.
Texto completoLongo, Vito, Oronzo Brunetti, Amalia Azzariti, Domenico Galetta, Patrizia Nardulli, Francesco Leonetti y Nicola Silvestris. "Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review". Cancers 11, n.º 4 (15 de abril de 2019): 539. http://dx.doi.org/10.3390/cancers11040539.
Texto completoHong, Xin, Ryan J. Sullivan, Mark Kalinich, Tanya Todorova Kwan, Anita Giobbie-Hurder, Shiwei Pan, Joseph A. LiCausi et al. "Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy". Proceedings of the National Academy of Sciences 115, n.º 10 (16 de febrero de 2018): 2467–72. http://dx.doi.org/10.1073/pnas.1719264115.
Texto completoAkhaladze, D. G., G. S. Rabaev, N. V. Zhukov, M. A. Pyatnitskiy, N. S. Gorochov, Y. A. Zhulikov, G. G. Rabaev, A. A. Kasatskiy, I. V. Volodin y N. V. Myakova. "INITIAL EXPERIENCE IN ESTIMATING TUMOR MUTATION BURDEN IN PEDIATRIC HEPATOCELLULAR CARCINOMA". Pediatria. Journal named after G.N. Speransky 100, n.º 3 (28 de mayo de 2021): 193–99. http://dx.doi.org/10.24110/0031-403x-2021-100-3-193-199.
Texto completoPatel, Amol, Dharmesh Soneji, Purvish Parikh y Manish Kumar. "Biomarkers in immuno-oncology: A review article". International Journal of Molecular & Immuno Oncology 4 (20 de mayo de 2019): 41–49. http://dx.doi.org/10.25259/ijmio-4-041.
Texto completoEl-Sayes, Nader, Alyssa Vito, Omar Salem, Samuel Tekeste Workenhe, Yonghong Wan y Karen Mossman. "A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner". International Journal of Molecular Sciences 23, n.º 3 (3 de febrero de 2022): 1754. http://dx.doi.org/10.3390/ijms23031754.
Texto completoMazloom, Anita, Nima Ghalehsari, Victor Gazivoda, Neil Nimkar, Sonal Paul, Peter Gregos, Janice Rateshwar y Uqba Khan. "Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies". Journal of Clinical Medicine 9, n.º 8 (6 de agosto de 2020): 2533. http://dx.doi.org/10.3390/jcm9082533.
Texto completoValente, Ana, Amy Gin, Allison Wells, Kai Ding y Kathleen Moore. "Exploring tumor mutational burden status and clinical benefit of immune checkpoint inhibitors in endometrial cancer". Gynecologic Oncology 164, n.º 1 (enero de 2022): 3–4. http://dx.doi.org/10.1016/j.ygyno.2021.10.046.
Texto completoKim, Jong Yeob, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin y Gabriele Gamerith. "Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis". Cancers 11, n.º 11 (15 de noviembre de 2019): 1798. http://dx.doi.org/10.3390/cancers11111798.
Texto completoRauterkus, Grant, Agreen Hadadi, Reagan Barnett, Caroline Weipert, Leylah Drusbosky, Xin Gao, Michael B. Lilly et al. "Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer." Journal of Clinical Oncology 40, n.º 6_suppl (20 de febrero de 2022): 165. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.165.
Texto completoCorrò, Claudia, Valérie Dutoit y Thibaud Koessler. "Emerging Trends for Radio-Immunotherapy in Rectal Cancer". Cancers 13, n.º 6 (18 de marzo de 2021): 1374. http://dx.doi.org/10.3390/cancers13061374.
Texto completoC Guven, Deniz, Taha K. Sahin, Omer Dizdar y Saadettin Kilickap. "Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives". Biomarkers in Medicine 14, n.º 14 (octubre de 2020): 1383–92. http://dx.doi.org/10.2217/bmm-2020-0310.
Texto completoOttini, Arianna, Pierangela Sepe, Teresa Beninato, Mélanie Claps, Valentina Guadalupi, Elena Verzoni, Patrizia Giannatempo, Giulia Baciarello, Filippo de Braud y Giuseppe Procopio. "Biomarker-driven immunotherapy for precision medicine in prostate cancer". Personalized Medicine 19, n.º 1 (enero de 2022): 51–66. http://dx.doi.org/10.2217/pme-2021-0079.
Texto completoCitra Wahyudin, Hendris Utama, Afriani Afriani, Fenty Anggrainy y Sabrina Ermayanti. "Immunotherapy in Lung Cancer: A Narrative Literature Review". Bioscientia Medicina : Journal of Biomedicine and Translational Research 7, n.º 1 (2 de marzo de 2023): 3024–30. http://dx.doi.org/10.37275/bsm.v7i1.755.
Texto completoBailey, Nathanael G. "Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement". Genes 13, n.º 3 (26 de febrero de 2022): 432. http://dx.doi.org/10.3390/genes13030432.
Texto completoKinget, Lisa, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel et al. "Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors". Current Oncology 28, n.º 5 (24 de agosto de 2021): 3227–39. http://dx.doi.org/10.3390/curroncol28050280.
Texto completoKoustas, Evangelos, Panagiotis Sarantis, Athanasios G. Papavassiliou y Michalis V. Karamouzis. "The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors". Biomolecules 10, n.º 5 (25 de abril de 2020): 666. http://dx.doi.org/10.3390/biom10050666.
Texto completoCortellini, Alessio. "The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC". JTO Clinical and Research Reports 1, n.º 4 (noviembre de 2020): 100080. http://dx.doi.org/10.1016/j.jtocrr.2020.100080.
Texto completoChen, Nan, Nicole Higashiyama y Valentina Hoyos. "Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1". Biomedicines 9, n.º 12 (8 de diciembre de 2021): 1863. http://dx.doi.org/10.3390/biomedicines9121863.
Texto completoOmuro, Antonio. "Immune-checkpoint inhibitors for glioblastoma: what have we learned?" Arquivos de Neuro-Psiquiatria 80, n.º 5 suppl 1 (mayo de 2022): 266–69. http://dx.doi.org/10.1590/0004-282x-anp-2022-s129.
Texto completoModur, Vishnu y Fukun Guo. "Tumors bearing defective transcription elongation are immune hot but resistant to immune checkpoint inhibitors". Journal of Immunology 208, n.º 1_Supplement (1 de mayo de 2022): 119.11. http://dx.doi.org/10.4049/jimmunol.208.supp.119.11.
Texto completoSaggese, Pasquale, Cesar Martinez, Linh Tran, Raymond Lim, Camelia Dumitras, Tristan Grogan, David Elashoff et al. "Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer". Cancers 13, n.º 14 (18 de julio de 2021): 3595. http://dx.doi.org/10.3390/cancers13143595.
Texto completoChokshi, Chirayu R., Benjamin A. Brakel, Nazanin Tatari, Neil Savage, Sabra K. Salim, Chitra Venugopal y Sheila K. Singh. "Advances in Immunotherapy for Adult Glioblastoma". Cancers 13, n.º 14 (7 de julio de 2021): 3400. http://dx.doi.org/10.3390/cancers13143400.
Texto completoPolano, Maurizio, Marco Chierici, Michele Dal Bo, Davide Gentilini, Federica Di Cintio, Lorena Baboci, David L. Gibbs, Cesare Furlanello y Giuseppe Toffoli. "A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning". Cancers 11, n.º 10 (15 de octubre de 2019): 1562. http://dx.doi.org/10.3390/cancers11101562.
Texto completoGolkaram, Mahdi, Chen Zhao, Kristina Kruglyak, Shile Zhang y Sven Bilke. "The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy". PLOS Computational Biology 16, n.º 11 (9 de noviembre de 2020): e1008332. http://dx.doi.org/10.1371/journal.pcbi.1008332.
Texto completoChen, Krista Y., Aleksandra Popovic, David Hsiehchen, Marina Baretti, Paige Griffith, Ranjan Bista, Azarakhsh Baghdadi et al. "Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors". Cancers 14, n.º 21 (30 de octubre de 2022): 5347. http://dx.doi.org/10.3390/cancers14215347.
Texto completoMiao, Diana, Claire Margolis, Dylan Martini, Stephanie Anne Mullane, Dana Cullen, Christine Horak, Megan Wind-Rotolo et al. "Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): 3016. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3016.
Texto completoVivaldi, Caterina, Silvia Catanese, Valentina Massa, Irene Pecora, Francesca Salani, Stefano Santi, Monica Lencioni, Enrico Vasile, Alfredo Falcone y Lorenzo Fornaro. "Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?" International Journal of Molecular Sciences 21, n.º 5 (28 de febrero de 2020): 1658. http://dx.doi.org/10.3390/ijms21051658.
Texto completoShao, Yusra F., Yasmine Baca, Joanne Xiu, Ari M. Vanderwalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay et al. "Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 9565. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9565.
Texto completoShao, Yusra F., Yasmine Baca, Joanne Xiu, Ari M. Vanderwalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay et al. "Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 9565. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9565.
Texto completoWang, Shuangkuai, Yuantao Tong, Hui Zong, Xuewen Xu, M. James C. Crabbe, Ying Wang y Xiaoyan Zhang. "Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types". Genes 13, n.º 2 (17 de febrero de 2022): 365. http://dx.doi.org/10.3390/genes13020365.
Texto completoGhidini, Michele, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco y Shelize Khakoo. "How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches". Journal of Clinical Medicine 10, n.º 7 (1 de abril de 2021): 1412. http://dx.doi.org/10.3390/jcm10071412.
Texto completoLi, Zhenxiang, Jiamao Lin, Lijuan Zhang, Jingchao Li, Yingyun Zhang, Chenglong Zhao y Haiyong Wang. "Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers". Future Oncology 16, n.º 29 (octubre de 2020): 2295–306. http://dx.doi.org/10.2217/fon-2020-0243.
Texto completoTruong, Cao-Sang y So Young Yoo. "Oncolytic Vaccinia Virus in Lung Cancer Vaccines". Vaccines 10, n.º 2 (4 de febrero de 2022): 240. http://dx.doi.org/10.3390/vaccines10020240.
Texto completoNgo, Carine y Sophie Postel-Vinay. "Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments". Biomedicines 10, n.º 3 (11 de marzo de 2022): 650. http://dx.doi.org/10.3390/biomedicines10030650.
Texto completoKosari, Farhad, Maria Disselhorst, Jun Yin, Tobias Peikert, Julia Udell, Sarah Johnson, James Smadbeck et al. "Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors". Journal of Thoracic Oncology 17, n.º 3 (marzo de 2022): 446–54. http://dx.doi.org/10.1016/j.jtho.2021.10.022.
Texto completoRuiz de Porras, Vicenç, Juan Carlos Pardo, Lucia Notario, Olatz Etxaniz y Albert Font. "Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?" International Journal of Molecular Sciences 22, n.º 9 (29 de abril de 2021): 4712. http://dx.doi.org/10.3390/ijms22094712.
Texto completoNandakumar, Vijayalakshmi y John R. Mills. "The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors". Clinical Chemistry 65, n.º 2 (1 de febrero de 2019): 357. http://dx.doi.org/10.1373/clinchem.2018.295097.
Texto completoSchrock, A. B., C. Ouyang, J. Sandhu, E. Sokol, D. Jin, J. S. Ross, V. A. Miller et al. "Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer". Annals of Oncology 30, n.º 7 (julio de 2019): 1096–103. http://dx.doi.org/10.1093/annonc/mdz134.
Texto completoRepáraz, David, Belén Aparicio, Diana Llopiz, Sandra Hervás-Stubbs y Pablo Sarobe. "Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?" International Journal of Molecular Sciences 23, n.º 4 (11 de febrero de 2022): 2022. http://dx.doi.org/10.3390/ijms23042022.
Texto completo